This two-day conference will serve as a platform to discuss compliance and transparency areas of key concern. Goal is to unravel compliance challenges, define and learn fair market value and develop a consistent, simple and transparent method and strategy for your company.
Interview with Marina Lavrova
Read the short interview with Marina Lavrova, Quality director, Sphera - Pharm, Russia.
As you are going to speak about the changes that you have implemented recently in your company, can you reveal what were the reasons for those changes?
All companies go through the changes – planned or unplanned. We understand that the change management system requires agreed decisions and integration with quality risk management processes.
Implementation of computer systems for managing changes provides with benefits such as:
- Absolute transparency of change management process
- Reduction of the amount of time needed for change implementation
- Risk-oriented approach to change management
- Decreasing the amount of mistakes
- Exclusion of hard copies
...and – as conclusion – reduction of the overall costs for managing poor quality of a product.
Interview was made for the 1st annual of the Quality Assurance in Russian Pharma Manufacturing conference which took place on 27-28 of May 2015 in Moscow, Russia.
Find out more about the upcoming event:
Interested in this topic?
Project & Portfolio Management for Pharma and Biotech – EAST
For the upcoming Project and Portfolio Management for Pharma and Biotech Conference, Fleming presents a high-level meeting building on more than a decade of experience in running global Pharma PPM events worldwide.
Patient Adherence and Engagement
Discuss the issues of non-adherence with other stakeholders and find a solution together with the patients themselves.
White Paper: Beyond the Cold Chain
Take a Good Look at the Future of Corporate Universities
There are four things corporate universities can do to avoid becoming irrelevant in the digital age.
Ready for the new GCP ICH E6 (R2) addendum?
On the 23rd of July 2015, the EMA's Committee for Human Medicinal Products released the Guideline for Good Clinical Practice E6(R2) for consultation. On the 14th of June 2017, it will come into effect and influence everyone involved in the clinical research process. What does it mean to pharma and biotech companies, sponsors, CROs, research institutes and third-party organizations?